Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- Cancer -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (478)	2/20/2004 12:23:11 PM
From: nigel bates	Respond to of 1840

LGND / STAT This is the Ligand patent FWIW: United States Patent 5,707,803 Lamb , et al. January 13, 1998 ------------------------------------------------------------------------ DNA regulatory elements responsive to cytokines and methods for their use Abstract The present invention provides oligonucleotide sequences comprising DNA regulatory elements comprising point mutations of Ly6E GAS element that bind activated transcriptional regulatory proteins in response to signaling molecules, such as cytokines. Further, the present invention also provides DNA constructs comprising the oligonucleotide sequences, cells transfected with the DNA constructs, and methods of using the DNA constructs and transfected cells to provide for the controlled expression of structural genes, for the detection and recovery of transcriptional regulatory proteins, and for measuring the ability of compounds to act as agonist and antagonists of gene transcription. ------------------------------------------------------------------------ Inventors: Lamb; Ian Peter (San Diego, CA); Seidel; H. Martin (San Diego, CA) Assignee: Ligand Pharmaceuticals, Inc. (San Diego, CA) Appl. No.: 410780 Filed: March 27, 1995... ...What is claimed is: 1. An isolated DNA molecule 13 to 200 nucleotides in length comprising at least one regulatory element that binds to an activated transcriptional regulatory protein, said regulatory element comprising a nucleotide sequence of TATTCCTGGAAGT (SEQ ID No. 1), TATTCCGGTAAGT (SEQ ID No. 2), TCTTCCTGTAAGT (SEQ ID No. 3), TATTCCCGTAAGT (SEQ ID NO. 6), or TATTCCTATAAGT (SEQ ID No. 7). 2. The isolated DNA molecule according to claim 1, wherein the transcriptional regulatory protein comprises a STAT protein. 3. The isolated DNA molecule according to claim 2, wherein the STAT protein is selected from the group consisting of STAT1.alpha. protein, STAT1.beta. protein, STAT2 protein, STAT3 protein, STAT4 protein, STAT5 protein and STAT6. 4. The isolated DNA molecule according to claim 1, wherein the regulatory element binds to an activated transcriptional regulatory protein comprising STAT1.alpha. protein in response to a cytokine that activates the STAT1.alpha. protein. 5. The isolated DNA molecule according to claim 1, wherein the regulatory element binds to an activated transcriptional regulatory protein comprising STAT1.alpha. protein or STAT3 protein in response to a cytokine that activates the STAT1.alpha. protein or the STAT3 protein. 6. The isolated DNA molecule according to claim 5, said regulatory element comprising a nucleotide sequence of TATTCCCGTAAGT (SEQ ID No. 6), or TATTCCTATAAGT (SEQ ID No. 7). 7. The isolated DNA molecule according to claim 1, wherein the regulatory element binds to activated transcriptional regulatory proteins comprising STAT1.alpha. protein, STAT3 protein, STAT5 protein or STAT6 protein in response to a cytokine that activates the STAT1.alpha. protein, STAT3 protein, STAT5 protein or STAT6 protein.... ...FIELD OF THE INVENTION This invention relates to oligonucleotide sequences that bind regulatory proteins that affect transcription in response to various molecules, such as cytokines, to DNA constructs comprising the oligonucleotide sequences, cells transfected with the DNA constructs, and to methods of using the same to provide for the controlled expression of heterologous genes, for the detection and recovery of new regulatory proteins, and for measuring the ability of compounds to act as agonist and antagonists of gene transcription....